Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Equinor ASA (EQNR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Equinor ASATrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Equinor ASA vs Neurocrine Biosciences Inc — how do they compare? Equinor ASA trades at $40.47 (market cap $97.58B), while Neurocrine Biosciences Inc trades at $161.12 (market cap $16.46B). The key difference: Equinor ASA is far larger — about 5.9× Neurocrine Biosciences Inc's market cap, and Equinor ASA pays a 3.81% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

EQNRNBIX
Market Cap
$97.58B$16.46B
Sector
EnergyHealth
52-Week High
$42.40$185.50
52-Week Low
$22.41$123.10
Enterprise Value
$106.28B$16.48B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Equinor ASA

No Aura AI signal available yet.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

About Equinor ASA

Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.

Read more on EQNR

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX